| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185488 | Gynecologic Oncology | 2013 | 6 Pages |
Abstract
Bevacizumab and docetaxel administered in patients with recurrent ovarian cancer is an active regimen without new unanticipated toxicities. This combination should be an option for further study or clinical use in recurrent ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Robert M. Wenham, James Lapolla, Hui-Yi Lin, Sachin M. Apte, Johnathan M. Lancaster, Patricia L. Judson, Jesus Gonzalez-Bosquet, Amber Herschberger, Laura J. Havrilesky, Angeles Alvarez Secord,